Celemics, Inc. Logo

Celemics, Inc.

Develops custom NGS panels and bioinformatics for research and clinical diagnostics.

331920 | KO

Overview

Corporate Details

ISIN(s):
KR7331920009
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 131, A동 19층 및 20층 2004호 외, 금천구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celemics, Inc. is a biotechnology company specializing in Next-Generation Sequencing (NGS) solutions for research and clinical diagnostics. The company develops and manufactures a comprehensive portfolio of products, including hybridization-based NGS target enrichment panels, whole exome sequencing (WES) kits, library preparation kits, and bioinformatics analysis services. Utilizing proprietary technologies in probe design, molecular barcoding, and bioinformatics, Celemics provides both ready-to-use and fully customized panels tailored for various applications. Its key markets include oncology, liquid biopsy, biopharma, inherited disease analysis, pharmacogenomics, pathogen detection, and agrigenomics, offering end-to-end solutions from assay development to data analysis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-05-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.8 KB
2025-03-27 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.2 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.1 KB
2025-03-19 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 430.2 KB
2025-03-19 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.5 MB
2025-03-04 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.8 KB
2025-03-04 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 158.7 KB
2025-03-04 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.3 KB
2025-03-04 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 159.1 KB
2025-02-19 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB
2024-12-17 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 9.6 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.1 MB

Automate Your Workflow. Get a real-time feed of all Celemics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Celemics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Celemics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.